Porsolt & Partners is a Contract Research Organisation involved in Animal Pharmacology
The services provided are orientated in 2 directions.
Efficacy:
The aim of these services is to assess novel substances for potential therapeutic activity in the various domains.
Safety:
Similar techniques are used for establishing whether the substance selected for a chosen indication is without risk on vital functions.
We also determine drug efficacy assessing novel substances for potential therapeutic activity in the various domains.
Porsolt's work covers many areas of research including: cardiovascular, respiratory, renal and gastrointestinal pharmacology, CNS and cardiac electrophysiology, antidepressants, anxiolytics and antipsychotics, sleep and epilepsy, acute and chronic pain, drug abuse and dependence, aging and memory, and phenotypic characterization.
Contact:
| Martine Lemaire | Senior Director, Scientific & Business Development |
Porsolt & Partners is a Contract Research Organisation involved in Animal Pharmacology
Safety Assessment Services:
Our Techniques can establish whether the substance selected for a chosen indication is without risk on vital functions.
We also determine drug efficacy assessing novel substances for potential therapeutic activity in the various domains.
Porsolt's work covers many areas of research including: cardiovascular, respiratory, renal and gastrointestinal pharmacology, CNS and cardiac electrophysiology, antidepressants, anxiolytics and antipsychotics, sleep and epilepsy, acute and chronic pain, drug abuse and dependence, aging and memory, and phenotypic characterization.
Contact:
| Martine Lemaire | Senior Director, Scientific & Business Development |
| Martine Lemaire | Senior Director, Scientific & Business Development |
Argenta Discovery and Porsolt Join Forces to Provide Fully-integrated CNS and Pain Contract Drug Discovery Services (13 May 2009)
The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination.
Porsolt & Partners Pharmacology announces expansion of Operations and Global Business Development (9 Apr 2009)
Porsolt & Partners Pharmacology announces expansion of Operations and Global Business Development
Porsolt & Partners Pharmacology - Appointment of Dr. Mark Duxon as CEO (15 Jul 2008)
Porsolt & Partners Pharmacology announces the appointment of Dr. Mark Duxon as Chief Executive Officer (CEO) of the company in September 2008
Porsolt & Partners Pharmacology Co-Marketing Agreement with Maccine (16 Apr 2007)
Partnership Porsolt & Partners Pharmacology with Maccine
Porsolt & Partners Pharmacology is an independent Contract Research Organization. As a niche CRO, we specialize in animal pharmacology, concentrating on our recognized excellence in selected domains of competence. We have been providing tailored and high quality solutions for over twenty years.
Psychopharmacology was a cornerstone of our company at its inception in 1984 (under the name ITEM-LABO). Since then the range of our activities has steadily broadened. We now cover other areas of central nervous system pharmacology, including pain and, since 1997, cardiovascular, respiratory, gastro-intestinal, and renal/urogenital pharmacology. More recent developments have been in the area of metabolism & eating disorders, and we have been extended our capacity for ex vivo and in vitro tests such as cellular electrophysiology, patch-clamp and isolated tissues. We also carry out phenotype characterization of transgenic and mutant mice.
We perform both efficacy and safety studies in these areas and on the basis of the continued improvement in our standards we were awarded a Grade A GLP compliance certificate from the French government.
Our Research facilities in the Mayenne region cover an area of 2 500 m². The construction of a new Research Center of about 6 000 sqm is planned in 2008. We have 250 m² offices near Paris.
We currently work with more than 100 different companies from Europe, North America, Israel, India and Australasia, of which 40 have been repeat clients for more than 3 years (repeat business). Our sponsors are evenly divided evenly between big pharma, small/mid/size pharma and start-up/biotech companies. Our data have been used to advance numerous substances towards clinical development.
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
